Partnerships

Open-Innovation Strategy

HiFiBiO Therapeutics is committed to working with leading pharmaceutical and biotechnology companies, as well as academic and reseach institutions to rapidly advance innovative therapies that can address the unmet medical needs of patients around the world.

We leverage our Open-Innovation model to establish strategic partnerships with collaborators in mutually beneficial relationships.

Our industry leading proprietary CelliGOTM platform and unique DISTM capabilities offer novel pathways for accelerating the discovery and development of high-quality therapeutic antibodies. They also enable biomarker discovery for advanced patient stratification and enhanced probability of clinical success.

We are currently engaged in several innovative partnerships to discover and validate novel therapeutic targets, and to identify rare functional antibodies against particularly complex targets. We are also applying our differentiated single-cell profiling capabilities to address pain points in the clinical development of novel therapeutics.

Contact us today to learn more about our open-innovation strategies and partnerships

  • By submitting this form you agree to our Privacy Policy.

We welcome inquiries from prospective partners interested in

Pipeline

  • Supporting our pipeline progression - internalizing innovative technologies and platforms that help generate the best molecules and maximize value
  • In-licensing of immunomodulatory assets synergistic with our internal pipeline
  • Partnering on internally developed immunomodulatory programs

Single-cell platform technologies

  • Discovering and validating novel immunomodulatory targets
  • Generating high quality therapeutic antibodies against targets of interest, including rare functional antibodies against complex targets (e.g GPCRs, ion channels)
  • Enhancing applications and technologies for our single-cell platform
  • Discovering antibodies from patient samples
  • Profiling tumor microenvironment
  • Leveraging our DISTM platform for single-cell biomarker discovery and validation

Other Areas

  • Developing emerging technologies for antibody therapeutics
  • Boosting big data analysis/processing capabilities through specialized AI/machine learning platforms

Pipeline

  • Supporting our pipeline progression - internalizing innovative technologies and platforms that help generate the best molecules and maximize value
  • In-licensing of immunomodulatory assets synergistic with our internal pipeline
  • Partnering on internally developed immunomodulatory programs

Single-cell platform technologies

  • Discovering and validating novel immunomodulatory targets
  • Generating high quality therapeutic antibodies against targets of interest, including rare functional antibodies against complex targets (e.g GPCRs, ion channels)
  • Enhancing applications and technologies for our single-cell platform
  • Discovering antibodies from patient samples
  • Profiling tumor microenvironment
  • Leveraging our DISTM platform for single-cell biomarker discovery and validation

Other Areas

  • Developing emerging technologies for antibody therapeutics
  • Boosting big data analysis/processing capabilities through specialized AI/machine learning platforms
Ready for the next steps? Contact us to learn more